StudyFinder
MT2021-26: Ruxolitinib for Early Lung Dysfunction after HSCT: a Phase II Study
Status: Recruiting
While hematopoietic stem cell transplant (HSCT) is an effective therapy, as many as 25% of patients develop problems with their lungs as a result of this treatment. Bronchiolitis obliterans (BO) is a type of lung injury after HSCT due to graft versus host disease. BO is commonly diagnosed late in patients, when lung injury is hard to treat and can be irreversible, leading to long-term lung disease or even death. The purpose of this research is to learn more about ruxolitinib as an early treatment for lung injury and BO after HSCT. Patients who are diagnosed with early lung dysfunction will be eligible for this research study.
Sex: Male or Female
Age Group: Not specified
Inclusion Criteria:
• 5 to 60 years old
• undergone allogeneic HCT and experiencing respiratory difficulty
• if able to become pregnant or father a child, must use two highly effective methods of birth control for 90 days after the last dose of study drug
• see link to clinicaltrials.gov for complete inclusion and exclusion criteria
Exclusion Criteria:
• active uncontrolled pulmonary infection
• women who are pregnant or breast feeding
• treated with investigational agent for GVHD within the 30 days prior to first dose of study treatment
Interventions:
Drug: Ruxolitinib
Conditions:
Cancer
Keywords:
GVHD, Hematopoietic Stem Cell Transplant, HSCT, Lung, Respiratory
Study Contact: Samuel Goldfarb - goldf091@umn.edu
Principal Investigator: Samuel Goldfarb
Phase: PHASE2
IRB Number: STUDY00014986
See this study on ClinicalTrials.gov